Haloperidol

• Description :

  Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H315, H317, H319, H335, H361

• Target :

  Dopamine Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Haloperidol.html

• Purity :

  99.73

• Solubility :

  DMSO : 40 mg/mL (ultrasonic)

• Smiles :

  ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2

• Molecular Formula :

  C21H23ClFNO2

• Molecular Weight :

  375.86

• Precautions :

  H301, H315, H317, H319, H335, H361

• References & Citations :

  [1]Furuta Y, et al. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs. Br J Pharmacol. 1973 Jan;47 (1) :77-84|[2]Shah NS, et al. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice. J Pharmacol Exp Ther. 1973 Aug;186 (2) :297-304|[3]Lei K, et al. Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. Exp Anim. 2018 May 10;67 (2) :163-173. |[4]Guzen FP, et al. Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. Curr Protoc Neurosci. 2019 Jun;88 (1) :e68.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  D2 Receptor

• Citation 01 :

  ACS Omega. 2020 Nov 15;5 (46) :29935-29942.|ACS Omega. 2025 Oct 17;10 (42) :50208-50217.|Adv Sci (Weinh) . 2025 Sep;12 (33) :e02276.|BMC Endocr Disord. 2021 Nov 23;21 (1) :235.|Br J Pharmacol. 2021 Sep;178 (17) :3570-3586.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell. 2023 Nov 22;186 (24) :5347-5362.e24.|Clin Exp Pharmacol Physiol. 2021 Mar;48 (3) :370-380.|Environ Sci Technol. 2023 Sep 26;57 (38) :14162-14172.|Eur J Integr Med. 2021, 101322.|Eur J Pharmacol. 2023 Dec 15:961:176174.|Eur J Pharmacol. 2023 May 5:946:175647.|J Ethnopharmacol. 2021 Jun 12:273:113994.|Oncogenesis. 2025 Aug 21;14 (1) :31.|Phytomedicine. 2025 Jun:141:156707.|PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |University of South Carolina. 2025.|University of Zurich. 2025.|Behav Brain Res. 2022 Mar 26:422:113759.|EMBO Rep. 2022 Feb 3;23 (3) :e53191.

• CAS Number :

  [52-86-8]